

Francesca Tosetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1807577/publications.pdf>

Version: 2024-02-01

46
papers

2,097
citations

304743

22
h-index

233421

45
g-index

46
all docs

46
docs citations

46
times ranked

3390
citing authors

#	ARTICLE	IF	CITATIONS
1	ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4969.	4.1	11
2	Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect. <i>Haematologica</i> , 2021, , .	3.5	9
3	Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy. <i>Cancers</i> , 2020, 12, 1886.	3.7	19
4	Aspartate Î²-hydroxylase targeting in castration-resistant prostate cancer modulates the NOTCH/HIF1Î±/GSK3Î² crosstalk. <i>Carcinogenesis</i> , 2020, 41, 1246-1252.	2.8	16
5	Evaluation of Glycosylated PTGS2 in Colorectal Cancer for NSAIDS-Based Adjuvant Therapy. <i>Cells</i> , 2020, 9, 683.	4.1	11
6	Human Gut-Associated Natural Killer Cells in Health and Disease. <i>Frontiers in Immunology</i> , 2019, 10, 961.	4.8	101
7	Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells. <i>Oncolmunology</i> , 2018, 7, e1421889.	4.6	28
8	Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes. <i>ChemMedChem</i> , 2018, 13, 2119-2131.	3.2	7
9	Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector Î³Î³ T cells with antitumor activity. <i>Oncolmunology</i> , 2017, 6, e1278099.	4.6	62
10	The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. <i>Cancer Letters</i> , 2017, 400, 9-17.	7.2	29
11	ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. <i>Oncolmunology</i> , 2016, 5, e1123367.	4.6	50
12	Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation. <i>Oncotarget</i> , 2015, 6, 12310-12325.	1.8	20
13	Glycogen Synthase Kinase 3 Regulates Cell Death and Survival Signaling in Tumor Cells under Redox Stress. <i>Neoplasia</i> , 2014, 16, 710-722.	5.3	19
14	On Arsenic and Plague. <i>Clinical Infectious Diseases</i> , 2014, 59, 1806-1808.	5.8	2
15	The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-Î± production. <i>Journal of Translational Medicine</i> , 2013, 11, 108.	4.4	136
16	Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity. <i>European Journal of Cancer</i> , 2013, 49, 3353-3365.	2.8	32
17	Cancer prevention by targeting angiogenesis. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 498-509.	27.6	264
18	Xanthohumol Impairs Human Prostate Cancer Cell Growth and Invasion and Diminishes the Incidence and Progression of Advanced Tumors in TRAMP Mice. <i>Molecular Medicine</i> , 2012, 18, 1292-1302.	4.4	63

#	ARTICLE	IF	CITATIONS
19	Response: Re: Neurocognitive Functioning in Adult Survivors of Childhood Noncentral Nervous System Cancers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 608-609.	6.3	2
20	Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention. <i>Current Drug Targets</i> , 2011, 12, 1909-1924.	2.1	36
21	Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 2-14.	4.4	39
22	The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3 β pathway and β -catenin stability. <i>Molecular Cancer</i> , 2010, 9, 142.	19.2	40
23	Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. <i>International Journal of Cancer</i> , 2009, 125, 1997-2003.	5.1	64
24	Anti-angiogenic properties of Chemopreventive Drugs: Fenretinide as a Prototype.. <i>Recent Results in Cancer Research</i> , 2009, 181, 71-76.	1.8	19
25	The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. <i>International Journal of Cancer</i> , 2008, 123, 1770-1778.	5.1	73
26	Glycogen Synthase Kinase 3 β Regulates Cell Death Induced by Synthetic Triterpenoids. <i>Cancer Research</i> , 2008, 68, 6987-6996.	0.9	36
27	Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor- κ B and p53 modulation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2692-2702.	4.1	73
28	Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 286-298.	4.1	23
29	Identification of a new truncated form and deamidation products of fibrinopeptide B released by thrombin from human fibrinogen. <i>Thrombosis and Haemostasis</i> , 2006, 96, 302-308.	3.4	5
30	Choking Hypoxia-Inducible Factor 1 α : A Novel Mechanism for Connective Tissue Growth Factor Inhibition of Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 946-948.	6.3	2
31	Tumor Inflammatory Angiogenesis and Its Chemoprevention. <i>Cancer Research</i> , 2005, 65, 10637-10641.	0.9	184
32	Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. <i>Cancer Detection and Prevention</i> , 2003, 27, 229-238.	2.1	62
33	N-(4-Hydroxyphenyl)retinamide Inhibits Retinoblastoma Growth through Reactive Oxygen Species-Mediated Cell Death. <i>Molecular Pharmacology</i> , 2003, 63, 565-573.	2.3	42
34	“Angioprevention”™: angiogenesis is a common and key target for cancer chemopreventive agents. <i>FASEB Journal</i> , 2002, 16, 2-14.	0.5	309
35	The Angiogenic Switch in Solid Tumors: Clinical Implications. <i>Tumori</i> , 2002, 1, S9-S11.	1.1	8
36	Transient modulation of cytoplasmic and nuclear retinoid receptors expression in differentiating human teratocarcinoma NT2 cells. <i>Journal of Neurochemistry</i> , 2002, 84, 94-104.	3.9	10

#	ARTICLE	IF	CITATIONS
37	The angiogenic switch in solid tumors: clinical implications. I Supplementi Di Tumori, 2002, 1, S9-11.	0.1	4
38	Growth factor supplemented matrigel improves ectopic skeletal muscle formation? a cell therapy approach. Journal of Cellular Physiology, 2001, 186, 183-192.	4.1	47
39	Studies on the Cellular Uptake of Retinol Binding Protein and Retinol. Experimental Cell Research, 1999, 250, 423-433.	2.6	7
40	Retinol Binding Protein and Transthyretin Are Secreted as a Complex Formed in the Endoplasmic Reticulum in HepG2 Human Hepatocarcinoma Cells. Experimental Cell Research, 1996, 222, 77-83.	2.6	66
41	A Retinoic Acid Resistant HL-60 Cell Clone Sensitive to N-(4-hydroxyphenyl) Retinamide-Mediated Clonal Growth Inhibition. Leukemia and Lymphoma, 1995, 17, 175-180.	1.3	8
42	An Improved RT-PCR Protocol for the Quantitation of Human Retinoic Acid Receptor RNA. Experimental Cell Research, 1994, 211, 121-126.	2.6	8
43	Regulation of plasma retinol binding protein secretion in human HepG2 cells. Experimental Cell Research, 1992, 200, 467-472.	2.6	17
44	Histone acetylation in conjugating Tetrahymena thermophila [published erratum appears in J Cell Biol 1989 Dec;109(6 Pt 1):3214-7]. Journal of Cell Biology, 1989, 109, 1007-1014.	5.2	16
45	Histone hyperacetylation is induced in chick erythrocyte nuclei during reactivation in heterokaryons*1. Experimental Cell Research, 1988, 178, 25-30.	2.6	16
46	Denitrosation of N-Nitrosodimethylamine and N-Nitrosomethylurea by liver microsomes from trout (Salmo gairdneri Rich.). Environmental Research, 1987, 42, 366-371.	7.5	2